U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07219576) titled 'Retifanlimab and Ruxolitinib In Solid Malignancies' on Oct. 20.
Brief Summary: The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma.
The main question it aims to answer is:
What is the maximum dose of ruxolitinib that can be used safely in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma, and will it work?
Participants will:
Take drug ruxolitinib twice a day and keep a diary of when they take ruxolitinib at home; visit the clinic for infusions of retifanl...